Lanreotide is a synthetic somatostatin analog classified as a peptide receptor agonist used in the long-term management of acromegaly and the treatment of symptoms associated with neuroendocrine tumors,… Read more

















Lanreotide is a synthetic somatostatin analog classified as a peptide receptor agonist used in the long-term management of acromegaly and the treatment of symptoms associated with neuroendocrine tumors, such as carcinoid syndrome. By binding to somatostatin receptors, particularly subtypes 2 and 5, it suppresses the secretion of growth hormone and various other regulatory peptides. Pharmaceutical laboratories utilize high-quality reference standards of lanreotide, alongside its specific impurities and metabolites, for critical analytical testing and quality control processes. These include rigorous impurity profiling to identify process-related or degradation-derived substances in accordance with regulatory guidelines. Furthermore, stable isotope labelled compounds are essential for method validation and precise quantification, serving as reliable internal standards in complex analytical techniques like liquid chromatography-mass spectrometry to ensure the accuracy, safety, and therapeutic consistency of the final drug product.